Reproductive Health Drugs Panel Holds On To Hager For A New Term
This article was originally published in The Tan Sheet
Executive Summary
House members critical of FDA's "not approvable" decision on OTC emergency contraception were unsuccessful in blocking the reappointment of David Hager, MD, University of Kentucky, to the agency's Reproductive Health Drugs Advisory Committee
You may also be interested in...
Crawford Nomination Woes Grow With Coburn Hold, Hager Letter
FDA Acting Commissioner Lester Crawford's bid for the permanent post has been cast further into doubt by a Republican joining the list of Senators threatening holds on his nomination
Crawford Nomination Woes Grow With Coburn Hold, Hager Letter
FDA Acting Commissioner Lester Crawford's bid for the permanent post has been cast further into doubt by a Republican joining the list of Senators threatening holds on his nomination
Crawford Nomination Woes Grow With Coburn Hold, Hager Letter
FDA Acting Commissioner Lester Crawford's bid for the permanent post has been cast further into doubt by a Republican joining the list of Senators threatening holds on his nomination